CHOLESTEROL EFFLUX MEDIATOR Trademark

Trademark Overview

On Friday, February 24, 2023, a trademark application was filed for CHOLESTEROL EFFLUX MEDIATOR with the United States Patent and Trademark Office. The USPTO has given the CHOLESTEROL EFFLUX MEDIATOR trademark a serial number of 97810486. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Wednesday, July 24, 2024. This trademark is owned by ZyVersa Therapeutics, Inc.. The CHOLESTEROL EFFLUX MEDIATOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of renal diseases and disorders
cholesterol efflux mediator

General Information

Serial Number97810486
Word MarkCHOLESTEROL EFFLUX MEDIATOR
Filing DateFriday, February 24, 2023
Status645 - FINAL REFUSAL - MAILED
Status DateWednesday, July 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of renal diseases and disorders
NOT AVAILABLECHOLESTEROL EFFLUX

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameZyVersa Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWeston, FL 33326

Trademark Events

Event DateEvent Description
Sunday, November 26, 2023ASSIGNED TO EXAMINER
Tuesday, February 28, 2023NEW APPLICATION ENTERED
Wednesday, March 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 5, 2023NON-FINAL ACTION E-MAILED
Tuesday, December 5, 2023NON-FINAL ACTION WRITTEN
Tuesday, December 5, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 26, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, January 26, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, January 29, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, January 29, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 29, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, June 4, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 4, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 4, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 4, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, March 4, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, October 2, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, October 2, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, July 24, 2024FINAL REFUSAL WRITTEN
Wednesday, July 24, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, July 24, 2024FINAL REFUSAL E-MAILED

Related Keywords

mediator efflux cholesterol diseases disorders renal treatment preparations pharmaceutical